title: Effect of hemolytic and iron-deficiency anemia on intestinal absorption and tissue accumulation of cadmium.
abstract: Abnormal iron (Fe) metabolism induces iron-deficiency anemia (FeDA) and also affects body cadmium (Cd) accumulation. However, whether hemolytic anemia also affects Cd metabolism is not known. We compared the intestinal absorption and tissue accumulation of Cd after oral administration of Cd to mice with hemolytic anemia induced by treatment with phenylhydrazine (PHA mice) to that in mice with FeDA. Although the hematocrit decreased significantly in mice with either type of anemia, the Fe concentration decreased in the livers and kidneys of FeDA mice, but increased in those of PHA mice. After an oral administration with various amounts of Cd, hepatic and renal Cd concentrations significantly increased in both FeDA and PHA mice. An intraduodenal injection of Fe raised the hepatic Fe content in FeDA mice to the control level and raised the hepatic Fe content in PHA mice to 2.4 times that in control mice. Intestinal divalent metal transporter 1 (DMT1) expression increased significantly in mice with both types of anemia. These data indicate that, despite the accumulation of hepatic Fe associated with PHA, PHA also significantly increases hepatic and renal Cd accumulation according to an stimulation of intestinal DMT1 expression, as occurs in FeDA mice. This suggests that anemia may be a risk factor for Cd accumulation.
authors.affiliation: Faculty of Pharmacy, Osaka Ohtani University, Tondabayashi, Osaka, Japan. minkyon@osaka-ohtani.ac.jp
authors.forename: Kyong-Son
authors.initials: KS
authors.lastname: Min
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Iwata
authors.forename: Noriko
authors.initials: N
authors.lastname: Tetsutikawahara
authors.forename: Satomi
authors.initials: S
authors.lastname: Onosaka
authors.forename: Keiichi
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D000284:Administration, Oral; D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000378:metabolism*; D018798:Anemia, Iron-Deficiency / Q000209:etiology / Q000378:metabolism*; D000818:Animals; D002104:Cadmium / Q000378:metabolism*; D019256:Cadmium Chloride / Q000008:administration & dosage / Q000493:pharmacokinetics*; D027682:Cation Transport Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004386:Duodenum / Q000378:metabolism; D005296:Ferrous Compounds / Q000494:pharmacology; D007267:Injections; D007408:Intestinal Absorption / Q000502:physiology*; D007501:Iron / Q000378:metabolism; D007554:Isotopes; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010659:Phenylhydrazines / Q000633:toxicity; D000099236:Solute Carrier Family 11, Member 2
chemical_list: D002104:Cadmium; D019256:Cadmium Chloride; D027682:Cation Transport Proteins; D005296:Ferrous Compounds; D007501:Iron; D007554:Isotopes; D010659:Phenylhydrazines; D000099236:Solute Carrier Family 11, Member 2; C030299:phenylhydrazine; C020748:ferrous sulfate